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Abstract: Cognitive symptoms are prevalent in the elderly and are associated with an elevated risk of
developing dementia. Disease-driven changes can cause cognitive disabilities in memory, attention,
and language. The inflammasome is an innate immune intracellular complex that has a critical
role in the host defense system, in that it senses infectious pathogen-associated and endogenous
danger-associated molecular patterns. An unbalanced or dysregulated inflammasome is associated
with infectious, inflammatory, and neurodegenerative diseases. Due to its importance in such
pathological conditions, the inflammasome is an emerging drug target for human diseases. A growing
number of studies have revealed links between cognitive symptoms and the inflammasome. Several
studies have shown that reducing the inflammasome component mitigates cognitive symptoms in
diseased states. Therefore, understanding the inflammasome regulatory mechanisms may be required
for the prevention and treatment of cognitive symptoms. The purpose of this review is to discuss
the current understanding of the inflammasome and its relationships with cognitive symptoms in
various human diseases.
Keywords: inflammasome; cognitive symptoms; neurodegenerative disease; inflammatory disease;
IL-18; IL-1β; caspase-1
1. Introduction
Cognitive impairment is common, and its prevalence is growing with the increase in the elderly
population [1]. In particular, pathological changes during disease processes are closely related to the
loss of cognitive abilities (memory, attention, and language) [2]. Many patients suffer from cognitive
impairment, which can result in the development of dementia [1,2]. The incidence of dementia continues
to increase from the age of 65 to 90 years and doubles every 5 years [3,4]. Pathologic phenotypes
such as amyloid plaque, neurofibrillary tangles, Lewy bodies, and macro- and micro-infarctions are
observed in the brain of elderly individuals [1,5,6]. Moreover, early activation of the microglia and
peripheral blood inflammatory changes are involved in cognitive decline and dementia [7,8].
Innate immunity is the first responder in the host defense system and monitors and clears both
sterile and infectious signs [9]. Innate immune cells expressing pattern recognition receptors (PRRs)
(nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), retinoic acid-induced gene
(RIG)-I-like receptors (RLRs), absent in melanoma 2 (AIM2)-like receptors (ALRs), Toll-like receptors
(TLRs), and C-type lectin receptors (CLRs)) can sense infectious foreign pathogen-associated molecular
patterns (PAMPs) and damaged or dying cell-derived endogenous danger-associated molecular pattern
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(DAMPs) [10,11]. Among them, the cytosolic NLR and ALR families form an intracellular complex—the
inflammasome—which binds through an adaptor protein, the apoptosis-associated speck-like protein
containing a carboxy-terminal CARD (ASC) and subsequently caspase-1 [9,12]. The inflammasome
plays pivotal roles in the maturation of pro-inflammatory interleukin (IL)-1β and IL-18 and triggers
pyroptosis, an inflammatory form of cell death [13].
The inflammasome is implicated in anti-microbial defense and tissue repair [14]. However, it can
drive human diseases, including inflammatory and neurodegenerative diseases. The association of
the inflammasome with cognitive symptoms and inflammasome-associated pathophysiology have
been reported in several pathological conditions [15–19]. Therefore, understanding the mechanisms
regulating the inflammasome complex may be important for preventing or treating cognitive disorders.
This review aims to discuss the current understanding of the inflammasome and its relationships with
cognitive symptoms in various human diseases.
2. Brief Overview of the Inflammasome
Cytosolic scaffold proteins of the NLR or ALR families, such as NLRP1, NLRP2, NLPR3, NLRC4,
NLRP6, NLRP7, NLRP12, and AIM2, are involved in inflammasome assembly [20,21]. A protein of the
NLR or ALR family can bind to the N-terminal pyrin domain (PYD) of ASC. The C-terminal caspase
activation and recruitment domain (CARD) of ASC can activate caspase-1 by linking pro-caspase-1
into the complex [9,12]. Caspase-1 regulates the maturation of pro-inflammatory IL-1β and IL-18 [13].
Canonical inflammasome-mediated caspase-1 and non-canonical inflammasome-mediated caspase-11
(human caspase-4 and 5) induce an inflammatory form of cell death, named pyroptosis [13,22,23].
Gasdermin D (GSDMD), cleaved by caspase-1 and caspase-11, is required during this process as an
executor/executioner of pyroptosis [24,25].
The NLRP3 inflammasome is formed by the NLRP3 protein, interacting through its PYD with
ASC, which, in turn, binds pro-caspase-1 through its CARD. NLRP3 activation is triggered by various
stimuli, including PAMPs, DAMPs, ion fluxes, and aggregated substances [26,27]. A two-step process
is required for NLRP3 activation: 1. A priming signal (mediated by TLR or TNFR) is involved in the
upregulation of NLRP3 and pro-IL-1β levels through the activation of transcription factor nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-κB) and post-translational modifications
of NLRP3. 2. A second signal induces and activates NLRP3 inflammasome assembly. NLRP3
inflammasome activation is closely associated with mitochondrial reactive oxygen species (ROS)
production, mitochondrial dysfunction, and lysosomal damage (Figure 1) [26–28].
The human NLRP1 protein has both PYD and CARD domains. The mouse genome encodes
three NLRP1 homologs, namely, NLRP1a, NLRP1b, and NLRP1c, which lack the PYD. They
can bind pro-caspase-1 directly via their CARD, without interacting with ASC. Therefore, the
NLRP1 inflammasome can lead to caspase-1 activation through an ASC-dependent manner or
through direct CARD-CARD interaction. The Bacillus anthracis lethal factor can activate the
NLRP1 inflammasome [9,27,29,30]. The involvement of NLRP1 in autoimmune diseases has been
suggested [30–33].
The NLRC4 protein has a CARD, which directly interacts with the CARD of pro-caspase-1,
without ASC, to form the inflammasome. Likewise, ASC can enhance the secretion of IL-1β and
IL-18 in the NLRC4 inflammasome [34]. A family of NLR apoptosis inhibitory proteins (NAIPs) can
sense flagellin and type-III secretion system (T3SS) components in the cytosol during infection by
bacteria such as Salmonella typhimurium and Shigella flexneri. The NAIPs can recruit NLRC4 to form
the inflammasome assembly [26,34,35]. The NLRC4 inflammasome is involved in the recognition of
intracellular bacterial pathogens and regulation of enteric infections [35,36]. NLRC4 has also been
associated with autoinflammatory diseases [35,37].
Moreover, AIM2 consists of a PYD and a DNA-binding HIN200 domain, so that it can recognize
cytosolic double-stranded DNA via the HIN200 and recruit ASC via the PYD. Microbial DNA from
intracellular pathogens (vaccinia virus (VACV), Francisella tularensis, Mycobacterium, and Listeria
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monocytogenes), type I interferons, and DNA from the host itself are critical for the activation of AIM2
inflammasome [38–41], which is essential for gut microbiota and intestinal homeostasis. Human
inflammatory and autoimmune diseases such as psoriasis, systemic lupus erythematosus, and atopic
dermatitis are related to AIM2 inflammasome (Figure 2) [41,42].
Figure 1. A two-step process for NLRP3 inflammasome activation. A priming signal is mediated by
TLRs or TNFR, which can activate the NF-κB pathway. The NF-κB transcription factor upregulates the
mRNA and protein levels of NLRP3 and pro-IL-1β. A second signal (Signal 2) is activated by various
stimuli including PAMPs and DAMPs, and directly promotes NLRP3 activation and inflammasome
assembly. Subsequently, the NLRP3 inflammasome is involved in the cleavage of pro-IL-1β and
pro-IL-18, leading to their activation. PAMPs, pathogen-associated molecular patterns; DAMPs,
danger-associated molecular patterns; TLRs; Toll-like receptors; tumor necrosis factor receptor (TNFR);
NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; LRR, leucine-rich repeat domain;
NACHT (also known as NBD), nucleotide-binding domain; PYD, pyrin domain; CARD, caspase
recruitment and activation domain; ROS, reactive oxygen species.
Figure 2. Schematic structure of NLRPs, ASC, and caspase-1. (A) Structures of inflammasome
sensors NLRP3, NLRP1, NLRC4, and AIM2. (B) Structures of inflammasome adaptor protein ASC
and (C) inflammasome effector pro-caspase-1. LRR; leucine-rich repeat domain, NACHT (or NBD);
nucleotide-binding domain, PYD; pyrin domain, CARD; caspase recruitment domain family, FIIND;
function-to-find domain, HIN200; 200-amino acid repeat.
NLRP6 can recognize enteric viruses and interact with viral RNA via RNA helicase Dhx15, an RNA
sensor, to promote type I/III interferons (IFNs) and IFN-stimulated genes [43]. NLRP6 is abundantly
detected in the intestinal epithelium and is important for colonic microbiota and gut immunity. NLRP6
in the intestinal epithelium is involved in the regulation of autophagy [44].
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3. Sepsis-Associated Encephalopathy
Sepsis is a condition caused by an infection (bacterial, fungal, or viral), leading to organ
dysfunction [45–47], and sepsis-associated encephalopathy (SAE) is a common complication of
sepsis [46,48]. SAE occurs in a large proportion (up to 70%) of patients in an intensive care unit suffering
from severe systemic inflammation [48]. Severe SAE patients have higher mortality rates [45,48]. SAE is
characterized by brain impairment and has been suggested as a cause of altered neurological and
mental states, including visuo-spatial deficits, memory loss, inattention, agitation, and disorientation.
When severe, it can lead to stupor and coma [46,49–51]. Magnetic resonance imaging (MRI) and
computerized tomography (CT) have shown that SAE manifests as extracranial abnormalities and
neurological disease-like changes [52]. In addition, MRI has revealed diverse brain injuries, ischemic
lesion, and white matter hyperintensities in the paraventricular or paramedian regions [53]. Along
with morphological changes in the brain, cognitive dysfunctions, including substantial new cognitive
deficits, can last long after hospitalization and eventually develop into dementia [54,55].
The pathophysiology of SAE has not been clearly elucidated yet, but an in vivo study of a cecal
ligation and puncture (CLP) model mimicking human sepsis or SAE has demonstrated through MRI the
presence of vasogenic and cytotoxic edema, as well as neuronal damage and brain injury [56]. Similarly,
in another study, MRI revealed cytotoxic edema and brain injury in a CLP model. Activated microglia
and inflammatory response were observed in several brain regions, such as the hippocampus, cortex,
and thalamus, of CLP mice [57]. Lipopolysaccharide (LPS)-injected mice showed inflammation-induced
blood-brain barrier (BBB) breakdown in specific brain regions, including the frontal cortex, striatum,
thalamus, and hippocampus. Changes in the water content in this model may be due to the breakdown
of the BBB. At the same time, inflammatory cytokines such as IL-lα, IL-1β, IL-3, IL-4, IL-9, IL-10,
monocyte chemoattractant protein-1 (MCP-1), and granulocyte-macrophage colony-stimulating factor
(GM-CSF) are abundantly expressed in the brain. In addition, inflammatory stimuli induce reactive
microglia and astrocytes, as well as the activation of peripheral macrophages/monocytes [58]. Similarly,
in a LPS injection model, the mice displayed breakdown of the BBB by detachment of pericytes from the
basal lamina and reactive microglia in the brain lesion [59]. Mice treated with LPS show anxiety-like
symptoms (as revealed by the elevated plus maze test) as well as depressive-like ones (tail suspension
test and sucrose preference test). In these mice, microglial markers, such as CD11b, Iba-1, and F4/80,
are highly expressed in the hippocampus; however, plasticity-related molecules and proliferating
neural stem cells are decreased in the brain [60]. Reactive microglia, neuroinflammation, and apoptotic
neuronal cell death have been suggested as potential causative factors of SAE [53].
Interestingly, the CLP model shows impaired spatial learning and memory in the Morris water
maze test and microglial activation, NLRP3 expression, and IL-1β cleavage in the hippocampus.
In a BV2 microglia cell line, LPS-treated microglia showed increased levels of NLRP3, caspase-1,
and IL-1β [61]. LPS-exposed mice display loss of recognition memory in a novel object recognition
test and long-term depression-like behaviors. In these mice, the NLRP3 complex components,
including NLRP3, ASC, and caspase-1 p10, and levels of IL-18, IL-1β, and tumor necrosis factor-α
(TNF-α) are increased in the hippocampus where microglial activation is observed. However, these
symptoms are reduced by a caspase-1 specific inhibitor, which suppresses NLRP3 inflammasome
activity [15]. Mice subjected to CLP exhibit hippocampal memory impairment in a fear conditioning test,
damaged hippocampal structure, activation of the NLRP3/caspase-1 pathway, increased pyroptosis,
and inflammatory cytokines such as IL-1β and IL-18; however, NLRP3 inhibition reversed these
outcomes after CLP injury [62], suggesting the involvement of NLRP inflammasome in SAE-associated
cognitive disorders.
In SAE models, resveratrol, Ac-Tyr-Val-Ala-Asp-chloromethylketone (Ac-YVAD-CMK), and
MCC950 show protective effects against inflammasome and cognitive dysfunction [15,61,62].
Resveratrol is a natural phenol known as a potential therapeutic agent in neurodegenerative diseases.
It is involved in the activation of sirtuin 1 (Sirt1) and inactivation of inflammatory proteins. In
both in vivo and in vitro systems, resveratrol inhibits NLRP3, caspase-1, and IL-1β expression in
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microglia cell lines. It also suppresses the NLRP3 inflammasome and IL-1β in the hippocampus,
thereby reducing spatial learning and memory in CLP mice [61]. Ac-YVAD-CMK, a caspase-1 inhibitor,
can reduce the expressions of NLRP3 inflammasome, IL-1β, and IL-18 in the hippocampus and attenuate
memory deficits and emotional abnormalities [15]. MCC950, an NLRP3 inhibitor, or Ac-YVAD-CMK
ameliorates neuronal pyroptosis and neuroinflammation in the hippocampus, thereby decreasing
cognitive impairment [62].
4. Perioperative Neurocognitive Disorders
Cognitive decline in patients following anesthesia and surgery is a common clinical symptom,
which may be a risk factor for dementia and death [63]. Following surgical procedures, the incidence
of cognitive impairment is estimated to be about 25% at 1 week and 10% at 3 months [64]. Among the
types of cognitive impairment seen during the perioperative period, delirium (acute confusional state)
is characterized by disturbed attention, cognition, and awareness [65]. Broadly defined, postoperative
cognitive dysfunction (POCD) is any decrement in cognition, such as learning and memory, perception,
and executive functions [66]. From 2018, the Nomenclature Consensus Working Group recommends
the use of the integrated term ‘perioperative neurocognitive disorders’ (PNDs) for cognitive impairment
or changes, including POCD and acute delirium, during the perioperative or postoperative phase [67].
The pathophysiology of PNDs has not been fully clarified; however, inflammatory response,
age, and anesthesia duration may be associated with PNDs [68–71]. Pain, disruption of circadian
rhythms, and systemic inflammation in response to surgery, infection, or injury are regarded as
causative factors of delirium, a specific form of PND [72–75]. Surgery-induced tissue damage may
trigger the peripheral immune response and release of inflammatory mediators. In particular, aged
mice showed neuroinflammation (upregulation of IL-1β) in the hippocampus and reduced cognitive
flexibility in the Morris water maze after minor abdominal surgery. However, anesthetics and
analgesics are not correlated with neuroinflammation [68]. Aged mice subjected to abdominal surgery
displayed increased hippocampal β-amyloid (Aβ) and beta-site APP cleaving enzyme (BACE1) levels
in the hippocampus and cognitive impairment, while general anesthesia did not cause such cognitive
deficits [76]. Abdominal surgery is involved in peripheral inflammation and infiltration of immune cells
via the disruption of the BBB, leading to neuroinflammation and cognitive impairment [69]. Moreover,
orthopedic surgery results in systemic inflammation, followed by IL-1β-mediated inflammation in
the plasma and hippocampus, and deficits in contextual fear memory. Such inflammatory response
and hippocampal microgliosis were reduced in IL-1 receptor (IL-1R) antagonist (IL-1RA)-treated mice
or IL-1R deficient mice [70]. Mice subjected to tibial fracture surgery exhibited neuroinflammation
and cognitive impairment due to TLR4/MyD88 signaling-mediated upregulation of S100A8 in the
peripheral blood mononuclear cells (PBMCs), spleen, and hippocampus; however, microgliosis was
reduced in both TLR4-deficient and MyD88-deficient mice and anxiety/cognitive dysfunction was
reversed in TLR4-deficient mice [71].
Moreover, the ME7 mouse model of prion diseases with systemic inflammation induced by LPS
exhibits acute and transient cognitive dysfunction, related to the pre-existing synapse loss and microglia
priming in the hippocampus. These mice also show markedly increased inflammatory mediators in
the central nervous system (CNS) [72]. Upregulated hippocampal and hypothalamic expressions of
IL-1β, TNF-α, and CCL2 were detected in ME7 mice after systemic injection of TNF-α, together with
acute loss of cognition and sickness behavior [73]. Additionally, pain after abdominal surgery resulted
in memory deficits and neuroinflammation in the medial prefrontal cortex and hippocampus, while
analgesics such as ropivacaine and morphine alleviated these symptoms [74].
The inflammasome has been reported to be related to the pathogenesis of PND in various murine
models [16,69,77,78]. In a mouse model subjected to anesthesia (isoflurane), aged mice, but not young
ones, showed activation of the NLRP3-caspase-1 pathway, poor performance in the Morris water maze,
and increased levels of IL-1β and IL-18 [16]. Moreover, in mice subjected to major abdominal surgery,
components of the NLRP1 inflammasome complex are expressed and IL-1β and IL-18 are highly
produced in the spleen, whereas the inhibition of the NF-κB p65 transcript reduced these effects [77].
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Surgical operation/anesthesia (sevoflurane) increases the activation of NLRP3 inflammasome, leading
to cognitive impairment. Interestingly, it was suggested that increased mitochondrial ROS and
malondialdehyde (MDA) production is associated with the NLRP3 inflammasome [78].
Ac-YVAD-CMK, NF-κB p65 inhibition, and Honokiol contribute to reducing the inflammasome
and ameliorating cognitive impairment in PND models [16,77,78]. Ac-YVAD-CMK can attenuate
anesthesia (isoflurane)-induced activation of NLRP3 inflammasome in aged brain, thus ameliorating
cognitive deficits [16]. Also, the inhibition of NF-κB p65, which is a transcriptional regulator for
inflammatory mediators, results in the reduction of NLRP1 inflammasome constituents and IL-18 and
IL-1β production in the spleen and reduction of cell death in the spleen. It also reduces long-term
potentiation (LTP) deficits and memory impairment [69,77]. Honokiol, a poly phenolic compound, has
anti-inflammatory, anti-oxidant, and anti-tumor properties and has shown inhibitory effects on NLRP3
inflammasome and restorative effects on cognitive impairment [78].
5. Multiple Sclerosis
Multiple sclerosis (MS) is a chronic auto-inflammatory demyelinating disease, in which nerves
are damaged by demyelination in the CNS [79]. MS patients show abnormalities in motor function,
muscle weakness, and sensorimotor dysfunction [80]. Brain MRI imaging reveals atrophy of both the
white and gray matter, with demyelination and axonal degeneration [81]. Approximately 40–60% of
MS patients develop cognitive impairments, affecting memory, executive function, and processing
speed [82,83]. Inflammation, demyelination, mitochondrial dysfunction, and axonal loss are the main
pathophysiological hallmarks of MS [84,85].
Many reports have discussed the association of inflammation and MS. During MS progression,
axonal lesions are correlated with inflammation and inflammatory infiltrates [86]. In agreement
with clinical observations, the experimental autoimmune encephalomyelitis (EAE) animal model
of MS shows alteration of brain volumes in the chronic phase of the disease. For example, EAE
mice undergo regional volume loss in both white and gray matter, including the hippocampus,
cerebral cortex, and cerebellum, accompanied by axonal loss and demyelination [87]. EAE mice
display activated microglia-derived IL-1β-dependent alterations in γ-aminobutyric acid (GABA)-ergic
activity in the hippocampus, suggesting that pronounced aberrant synaptic plasticity could result in
cognitive dysfunction [88]. As expected, LTP and spatial memory are impaired in the late stages of
EAE [89]. Similarly, EAE mice show persistent microglial activation and subsequent impairment of
long-term synaptic plasticity in the hippocampus. Such LTP damage is mediated by nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase and results in hippocampal-dependent cognitive
dysfunction. Conversely, the inhibition of NADPH oxidase can recover LTP and inhibition of microglial
activation also reverses synaptic and cognitive deficits [90].
The central role of the inflammasome has been demonstrated in MS [91,92]. Inflammasome-
associated genes, including NLRP3, IL-1β, IL-18, caspase-1, GSDMD, and ASC, are increased in the
postmortem brains of MS patients, and GSDMD is observed in the myeloid cells and oligodendrocytes of
MS lesions, indicating pyroptosis. Similar to MS patients, EAE mice show activation of inflammasome,
pyroptosis, and axonal injury in the CNS. Caspase-1 inhibition in EAE mice can reverse inflammasome
activation, pyroptosis in the myeloid cells and oligodendrocytes, and neurobehavioral deficits [91].
Systemic or splenic IL-1β and IL-8 are increased in EAE mice; however, NLRP3- or ASC-deficient mice
fail to induce IL-1β and IL-8 production [92]. EAE mice show increased NLPR3 expression in the spinal
cord, with increased infiltration of immune cells (CD4 T cell, CD8 T cell, macrophages, and dendritic
cells) and upregulated IL-18 in the serum and spinal cord. Genetic NLRP3 deficiency delays the
development and decreases the severity of the disease by suppressing the immune infiltrates into the
spinal cord and reducing T helper (Th)1 and Th17 T cell response, thus preventing the disruption
of the myelin sheath [17]. EAE mice, before demyelination, exhibit anxiety- and depression-like
behaviors and cognitive impairment, which are dependent on the increased IL-1β and TNF-α levels in
the hypothalamus [93]. Overexpression of IL-1β leads to MS-like pathologic phenotypes, including
neurodegeneration, demyelination, and inflammation, together with cognitive impairments [94].
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In an MS model, caspase-1 inhibitor VX-765 reduced inflammasome- and pyroptosis-associated
proteins in the spinal cord, alleviated neuropathological features such as axonal injury, and prevented
neurobehavioral deficits [91].
6. Alzheimer’s Disease
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by the progressive
impairment of memory and cognition, which can develop into dementia [95]. Early onset familial
AD is related to the mutation of genes, including presenilin 1 (PSEN1), presenilin 2 (PSEN2), and
amyloid precursor protein (APP) [95]. Apolipoprotein E(APOE) is responsible for both sporadic AD
and late-onset familial AD [95,96]. Despite such distinction, the clinical and pathologic phenotypes
are similar between familial and sporadic AD [95]. Increasing evidence suggests that impaired
autophagy, extracelluar Aβ deposition, intracellular neurofibrillary tangles of tau, and imbalanced
immune response are the main biological features of AD [97,98]. After cleaving by beta- or
gamma-secretase, APP produces Aβ, the main component of the amyloid plaque [99]. While tau, a major
microtubule-associated protein (MAP), plays an important role in the stabilization of microtubules,
its hyperphosphorylation can generate neurofibrillary tangles [100]. Normally, aggregate-prone
proteins, including Aβ, are removed by autophagy [97]. Under compromised autophagy, such as in
AD, the Aβ aggregates are markedly increased in the postmortem brain [97,101].
Immune cell activation and inflammatory response are observed as common hallmarks of AD [102].
The APP/PS1 and APP/PS1dE9 transgenic mouse models of AD display activated microglia and expresse
pro-inflammatory cytokines such as IL-1β, CXCL1, CCL3, and CCL4 [103]. Pro-inflammatory IL-18
increases APP expression and Aβ formation in the neuronal SH-SY5Y cell line [104]. In a rat primary
microglia and cortical neuronal cell culture, secreted APP alpha (sAPPα) from neuron can activate
microglia, which release IL-1β. Increased level of IL-1β is associated with elevated levels of α-synuclein
and tau hyperphosphorylation in neuron [105]. Interestingly, microglial LC3-associated endocytosis
has been suggested to contribute to protection against Aβ deposition and inflammatory response in an
AD model. Aβ1–42 exposure results in enhanced expression of pro-inflammatory cytokines such as
IL-1β, IL-6, and TNF-α in the BV2 microglia cell line and in primary microglia. Furthermore, deficiency
in LC3-associated endocytosis-related genes, including Atg5 and Rubicon, exacerbates the levels of
pro-inflammatory cytokines [106]. APPswe/PSEN1dE9 transgenic mice show loss of spatial learning
and memory, increased anxiety, and defects in social interaction, which are associated with amyloid
deposition in the cerebral cortex and hippocampus. In particular, reactive microglia and astrocytes
are observed around these amyloid depositions, and the same cells are involved in Aβ-induced
inflammatory response, producing IL-1β, IL-6, IL-17A, and TNF-α [107]. In addition, the APP21
transgenic rat model of AD, which expresses human APP, shows impaired executive functions, white
matter microglial activation and inflammation, and vulnerability to amyloid generation [108].
According to some studies, NLRP3 inflammasome is present in AD [18,109]. In the brain of
AD patients, high levels of cleaved (activated) caspase-1 are observed in the hippocampus and
cortex. Accumulation of Aβ is involved in microglial activation, and Aβ-induced activation of
the NLRP3 inflammasome is required for caspase-1 activation. The APP/PS1 mouse model of AD
exhibits phagocytic dysfunction for Aβ, synaptic dysfunction, and spatial memory impairment;
however, NLRP3 or caspase-1 deficiencies in these mice increase Aβ clearance, synaptic plasticity,
and memory function [109]. The NLRP1 inflammasome has reported as highly expressed in response
to Aβ accumulation in the brain of APPswe/PS1dE9 mice, and thus indicated as a mediator of Aβ
neurotoxicity; indeed, APPswe/PS1dE9 mice show neuronal pyroptosis in the hippocampus and
cortex and cognitive loss, while the genetic knockdown of NLRP1 or caspase-1 in this model reverses
pyroptosis and cognitive dysfunction [110]. The microglia may also be critical to the formation
of Aβ plaques by releasing inflammasome-dependent ASC specks, which directly bind to Aβ in
APPswe/PSEN1dE9 mice. In contrast, genetic ASC deficiency in APPswe/PSEN1dE9 mice shows a
beneficial role in the pathology of AD [111]. A previous study has reported that amyloid deposition
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and memory loss are increased in 5xFAD mice; however, ASC heterogeneity in these mice attenuates
these outcomes [112]. Furthermore, the NLRP3 inflammasome is responsible for the pro-inflammatory
and neurotoxic properties of Aβ via caspase-1 activation in the microglia stimulated with Aβ. A genetic
deficiency in caspase-1 can ameliorate neurotoxic effects and chemokine levels even after exposure to
Aβ, and the caspase-1 inhibitor z-YVAD-fmk attenuates IL-1β secretion in the microglia despite Aβ
stimulation [18].
In addition, MCC950 and VX-765 have shown protective effects in AD models [113,114].
MCC950 improved disrupted synaptic plasticity and LTP in transgenic rat overexpressing APP [113].
The caspase-1 inhibitor VX-765 suppressed both neuroinflammation and accumulation of Aβ in a J20
APP Sw/Ind transgenic mouse model of AD. Also, VX-765 attenuated learning and memory impairment
in this AD model [114].
7. Parkinson’s Disease
Parkinson’s disease (PD) is a progressive neurodegenerative disease featured by tremor, rigidity,
cognitive decline, and behavioral difficulties [115]. PD is characterized by dopaminergic neuronal
loss in the substantia nigra and intraneuronal Lewy bodies, mainly containing α-synuclein [115,116].
Furthermore, exosomal α-synuclein can confer cognitive impairment, even leading to dementia [117].
Both the ubiquitin-proteasome system (UPS) and autophagy may be involved in the degradation
of α-synuclein. However, impairment of the protein degradation system can lead to the formation
of neurotoxic α-synuclein aggregates [115,118,119]. It has been reported that oxidative stress and
inflammation are one of the main causes of PD [120,121].
In particular, growing evidence shows distinct inflammatory reactions in the pathogenesis
of PD [122]. Recruitment of peripheral immune cells, reactive microgliosis, and increased
pro-inflammatory mediators are observed in the brain of PD patients and in animal model of
PD [123–125]. In an intra-nigrally α-synuclein-injected model of PD, α-synuclein was shown to
induce the infiltration of peripheral myeloid cells into the CNS, which have pro-inflammatory
properties [123]. Extracellular α-synuclein is associated with the activation of microglia depending
on NADPH oxidase activity and ROS production [126]. Similarly, α-synuclein transgenic mice show
highly expressed reactive microglia in the substantia nigra and pro-inflammatory TNF-α. The microglia
under synuclein-incubated conditions induces TNF-α, COX2, NOX2, and iNOS [127]. A rat model of
PD using 6-hydroxydopamine (6-OHDA) presented impaired memory functions, increased reactive
microglia, and imbalance between pro- and anti-inflammatory mediators [128]. A53T transgenic mice
display motor and coordination impairment, consistent with the symptoms of PD patients. A53T mice
also present memory impairment, long-term depression, and synaptic impairment [129]. A53T mice
expressing mutant α-synuclein display increased inflammatory response, together with early cognitive
impairment [130].
It has been proved that inflammasome-related signals such as NLRP3 and IL-1β are expressed
in the serum, and NLRP3 inflammasome is closely correlated with α-synuclein in PD patients [131].
The previous study proved that in fibrillar α-synuclein or 6-OHDA injection mouse model of PD,
the NLRP3 inflammasome acts as a bridge between fibrillar α-synuclein and dopaminergic neuronal
loss. These mice show deficits in motor function and nigrostriatal dopaminergic neuron; however, the
inhibition of NLRP3 protects them from these associated symptoms [19]. Interestingly, α-synuclein
aggregation is influenced by caspase-1. A truncated form of α-synuclein, enriched in insoluble
aggregates and found in Lewy bodies, is formed by active caspase-1. Genetic/pharmacological
inhibition of caspase-1 plays an important role in reducing the truncation of α-synuclein in BE(2)-M17
neuronal cells overexpressing α-synuclein [132]. Also, α-synuclein is involved in IL-1β synthesis
and secretion through inflammasome and caspase-1 activation [133]. In a 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-induced PD model, mice showed severe motor deficit, loss of dopaminergic
neurons, and increased α-synuclein; however, these phenotypes were reduced by inhibiting NLRP3
inflammasome activation [134].
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In PD mouse models, MCC950 prevented the α-synuclein-induced activation of NLRP3
inflammasome, dopaminergic neuronal degeneration, and motor deficits [19]. Furthermore, VX-765
suppresses α-synuclein truncation and subsequent neurotoxicity by inhibiting caspase-1 [132].
8. Conclusions
In this review, we summarized the accumulated evidence on the relationships between the
inflammasome and cognitive symptoms in various disease conditions. Understanding the regulatory
mechanisms of the inflammasome is necessary to account for cognitive disorders in inflammasome-
driven diseases (Figure 3). A growing number of studies have revealed that the manipulation of
inflammasome components by genetic or pharmacological tools can restore cognitive dysfunction.
MCC950, VX-765, Ac-YVAD-CMK, or z-YVAD-fmk, which can downregulate inflammasome components,
exert beneficial effects on both cognition and pathophysiological features in human diseases, such
as inflammatory and neurodegenerative diseases. These observations suggest that the development
of drugs targeting the inflammasome can prevent a critical step in the progression toward cognitive
symptoms. In conclusion, biological evidence offers an important perspective on the relationships
between inflammasome and cognitive symptoms in the pathophysiology of several diseases
and suggests a significant potential relevance of the inflammasome in preventing and treating
cognitive symptoms.
Figure 3. Imbalanced or dysregulated inflammasomes are linked to inflammatory, and neurodegenerative
diseases. In these diseases, activation of inflammasome complex and pro-inflammatory cytokines IL-18
and IL-1β in immune cells are involved in neuronal damage and degeneration in the brain, in particular,
hippocampus and cerebral cortex. These outcomes may be related to cognitive symptoms. Therefore,
understanding the inflammasome regulatory mechanisms may be required for the prevention and
treatment of cognitive symptoms.
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ALR AIM2-like receptor
APOE apolipoprotein E
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DAMP danger-associated molecular pattern
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IL-1R IL-1 receptor
IL-1RA IL-1R antagonist
LPS lipopolysaccharide
LRR leucine-rich repeat
LTP long-term potentiation
MAP microtubule-associated protein
MCP-1 monocyte chemoattractant protein-1
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
MRI magnetic resonance imaging
MS multiple sclerosis
NACHT, NBD nucleotide-binding domain
NADPH nicotinamide adenine dinucleotide phosphate
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells
NLR NOD-like receptors
NOD nucleotide-binding oligomerization domain
PAMP pathogen-associated molecular pattern
PD Parkinson’s disease
PND perioperative neurocognitive disorder
POCD postoperative cognitive dysfunction
PYD pyrin domain
PRR pattern recognition receptor
PSEN presenilin
RIG retinoic acid-induced gene
RLR RIG-I-like receptor
ROS reactive oxygen species
SAE sepsis-associated encephalopathy
Sirt1 sirtuin 1
Th T helper
TLR Toll-like receptor
TNFR tumor necrosis factor receptor
VACV vaccinia virus
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